

MarketVue®

# Eosinophilic Esophagitis

October 2022



# MarketVue®: Eosinophilic Esophagitis

## UNDERSTAND THE EOSINOPHILIC ESOPHAGITIS MARKET

**MarketVue** market landscape reports combine primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.

Every **MarketVue** includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.

**Methodology:** Research is supported by 4 qualitative interviews with key opinion leaders (U.S. Gastroenterologists), a quantitative survey with 25 U.S. physicians and secondary research.

**Geographies covered:** United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)

### TOPICS COVERED

**EPIDEMIOLOGY:** Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments

**CURRENT TREATMENT:** Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment

**UNMET NEEDS:** Identify opportunities to address treatment or disease management gaps

**PIPELINE ANALYSIS:** Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs

**VALUE AND ACCESS:** Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing

## Why MarketVue?

- **PMR-Driven** – Insights informed by qualitative interviews and/or quantitative surveys
- **Senior Team** – Experienced team members (10+ years in pharma market research) lead the research
- **Strategic** – Delivered in a concise and strategic report template vetted by pharmaceutical industry professionals
- **Fresh** – New reports or report refreshes delivered in as little as 15 business days



# MarketVue®: Eosinophilic Esophagitis

UNDERSTAND THE EOSINOPHILIC ESOPHAGITIS MARKET

## COMPANIES MENTIONED

- Regeneron Pharmaceuticals
- Sanofi
- AstraZeneca
- Bristol-Myers Squibb
- Ellodi Pharmaceuticals
- EsoCap
- Pfizer
- Dr. Falk Pharma
- Revolo Biotherapeutics
- Amzell Pharma
- EMS

## DRUGS MENTIONED

- Corticosteroids
- Dupilumab (Dupixent)
- Benralizumab (Fasenra)
- Tezepelumab (Tezspire)
- Etrasimod (Velsipity)
- Cendakimab / CC-93538
- APT-1011 / fluticasone propionate
- ESO-101 / mometasone
- Mesalazine
- IRL201104
- Budesonide
- Florence

# MarketVue®: Eosinophilic Esophagitis

## Table of Contents

<b>1. DISEASE OVERVIEW</b>	<b>5 - 6</b>
A chronic, inflammatory disorder of the immune system in the esophagus, characterized by dysphagia, food impaction, and regurgitation	5
Figure 1.1. Pathophysiology of EoE	5
EoE is the most common form of EGID	6
Figure 1.2. Classification of EoE	6
Table 1.1 EoE and GERD are not mutually exclusive and can co-occur but have their own distinguishing features	6
<b>2. EPIDEMIOLOGY &amp; PATIENT POPULATIONS</b>	<b>7</b>
Disease definition	7
Figure 2.1 – G6 diagnosed prevalent cases of EoE by region	7
Table 2.1 – Diagnosed prevalent and drug-treated patients in the G6	7
<b>3. DIAGNOSIS AND CURRENT TREATMENT</b>	<b>8 - 17</b>
Diagnosis Overview	8
Figure 3.1. Diagnostic pathway for EoE patients	8
Figure 3.2. Gastroenterologist-Reported Misdiagnosis and Delayed Diagnosis Among EoE Patients	
Dietary therapy, PPIs and corticosteroids are the current standards of care	9
Treatment overview	9
Figure 3.3. Treatment goals for EoE	9
Figure 3.4. Current Treatment Patient Share	9
Treatment flow for EoE	10
Figure 3.5. Treatment algorithm for EoE	10
Physicians are satisfied with the efficacy of current treatments for EoE	11
Figure 3.6. Gastroenterologist rating (n=25) of current therapy effectiveness in EoE	11
Figure 3.7. Gastroenterologist-reported percentage of EoE patients who are refractory to current pharmacologic treatment options	11
Existing treatments work well but convenience could be improved for chronic use	12
Gastroenterologists' opinions on current treatments	13
Dupilumab is the first and only FDA-approved drug for EoE	14
Figure 3.8. Phase 3 results for Regeneron/Sanofi's dupilumab in EoE	14
Dupilumab is viewed favorably by physicians	15
Figure 3.9. Dupixent's advantages observed in clinical practice	15
Figure 3.10. Treatment dynamics observed in clinical practice	15

# MarketVue®: Eosinophilic Esophagitis

## Table of Contents

Key treatment dynamics that shape disease management and drug use in EoE	16
Table 3.1 Must-know EoE treatment dynamics	16
Figure 3.11. Percentage of drug-treated patients surveyed gastroenterologist estimate would be eligible for novel classes of EoE therapy	16
The EoE market may see significant shifts over the next decade	17
Figure 3.12. Important dynamics of EoE market evolution	17
<b>4. UNMET NEED</b>	<b>18 - 20</b>
Overview	18
Figure 4.1 – Top unmet needs in EoE	18
Figure 4.2 – Physician-reported unmet needs in EoE	18
Two groups of EoE patients exist whose needs can be met by novel therapeutics	19
Figure 4.3 – High need patient types in EoE	19
Figure 4.4. Percentage of gastroenterologists who see this as a barrier to receiving drug therapy	19
The need for new EoE treatments is moderate compared to other Gi/allergic conditions	20
Figure 4.5 – U.S. gastroenterologists rating of the need for new treatments in gastrointestinal and allergic conditions	20
<b>5. PIPELINE ANALYSIS</b>	<b>21 - 23</b>
Overview	21
Figure 5.1. Number of emerging therapies addressing unmet needs in EoE	21
Pipeline for EoE has many late-phase products primed for launch	22
Table 5.1. Comparison of ongoing trials in EoE	22
The earlier phase pipeline for EoE is not as active as the late-phase pipeline	23
Table 5.1. Comparison of ongoing trials in EoE (continued)	23
Late-phase pipeline	23
Figure 5.2. Percentage of gastroenterologists who rated the following emerging therapies as “promising”	23
<b>6. VALUE &amp; ACCESS</b>	<b>24 - 25</b>
Overview	24
Table 6.1 – Current therapy pricing	24
Table 6.2 – Typical commercial payer coverage of Rituxan and Dupixent (e.g., United Healthcare, Aetna, BlueCross BlueShield, Cigna)	24
Key market access dynamics that will continue to shape treatment use	25

# Meet the REACH Team



**DANIELLE DRAYTON, PhD.**, Dr. Drayton is CEO and Founder of REACH Market Research. She is a seasoned business leader and pharmaceutical market researcher. Prior to founding REACH, Dr. Drayton led the Biopharma Market Assessment business at Decision Resources Group (DRG) comprised of market research, RWD analytics, and consulting business lines. In her 14 years at DRG, she worked with 48 of the top 50 pharmaceutical companies and countless biotech companies that involved exhaustive evaluation of unmet need, target product profiles, commercial potential and new product adoption, and company competitiveness. She also has extensive experience conducting product and market opportunity assessments, portfolio analysis, product and therapeutic area strategy, product valuation and sales forecasting, and pre-launch planning. Dr. Drayton completed a postdoctoral fellowship at the Harvard Medical School, received a Ph.D. in Immunobiology from Yale University, and earned a B.S. in Microbiology and Immunology from the University of Miami (Florida).



**MELISSA CURRAN** is the Director of Product Management at REACH. Melissa has over 10 years of life sciences market research and consulting experience spanning from bespoke strategy consulting to syndicated market research product development and management. Prior to joining REACH, she worked at Decision Resources Group (DRG) for 7 years assisting pharmaceutical and biotechnology commercial teams across the product lifecycle to inform strategic decision making. Melissa is particularly passionate about new product planning and portfolio management, especially in the rare disease space where data can be scarce, and decision-making can be challenging. Specific types of strategic assessments Melissa specializes in include market landscape assessments, commercial opportunity assessment, patient journey mapping, product positioning and TPP optimization, portfolio prioritization, and competitive intelligence. She also has extensive experience working across various market research methodologies including qualitative interviews, quantitative surveys, patient chart audits, real world claims and EHR data, conjoint analysis and secondary research. Melissa received her bachelor's degree in Biology and minor in Business from Providence College.



**MICHAEL HUGHES, MSc, Ph.D.**, Dr. Hughes is the Director of Research at REACH. He has worked in academia, regulatory affairs (NICE) and in RWE and epidemiology consultancies, leading the global epidemiology team at Clarivate (previously Decision Resources Group) for many years. Over that period, he has built numerous new approaches to epidemiological forecasting and imputation, which now form industry best-practice. He has built syndicated and custom epidemiological models and forecasts for many blockbuster drugs across many therapeutic areas, often using a hybrid approach sourcing data from multiple types of dataset and primary market research. He has recently worked on projects in prostate cancer, amyloidosis, anaphylaxis and multi-drug resistant UTIs, among others. He has supported the needs of both big pharma, including Novartis, GSK and Johnson and Johnson, as well as smaller companies and biotechs.

# Meet the REACH Team



**TYLER JAKAB, MPH** is an analyst at REACH Market Research. He is responsible for conducting both primary and secondary market research regarding rare disease therapies to be integrated into market research reports for life science clients. Tyler is a recent graduate of Boston University School of Public Health where he obtained an MPH in Epidemiology of Biostatistics. Prior to joining REACH, he held roles in which he was responsible for health policy analysis, tobacco control research, and health communication. He has extensive experience in data analysis, as well as manuscript and report writing. Tyler also earned a BS in Psychology and Anthropology from the University of North Carolina at Chapel Hill.



**BAYLEY KOOPMAN** is a Research Associate at REACH Market Research. At REACH, Bayley supports both primary and secondary market research through literature reviews and working with qualitative data. He recently graduated from Tufts University with a B.S. in Biology where he studied the interdisciplinary OneHealth approach for public health and the environment. During this time, Bayley founded an early-stage consumer product startup, which became a finalist team in two consecutive Tufts University Entrepreneurship Pitch Competitions. Prior to joining REACH, Bayley also held roles in regulatory affairs in the rare-disease pharmaceutical industry and veterinary practice.



**BRIANA MULLINS** is a current PhD student At NYU School of Medicine studying the immunological progression of disease in psoriatic arthritis. She currently does both laboratory research and computational biology. Previously she earned her undergraduate degree in Biochemistry at New York University (NYU) and worked in the Blaser Lab studying the human microbiome. She also received an MSc. in Population Health at the University College London (UCL) and conducted antibiotic prescription research using the UK THIN Database. Before starting her PhD Briana worked at Decision Resources Group as an Associate Epidemiologist.